Bereiche

DOI

Link

Kontakt

---

Zitation

Art

Buchtitel

Veröffentlichungsdatum

Ausgabe

ISBN Nummer

Seiten

Verlag

Kurzbeschreibung/Zielsetzung

The early identification of predictive molecular markers is crucial. Activating EGF receptor mutations and ALK gene rearrangements occur in a subset of patients with non-small-cell lung cancer and predict for benefit of the treatment with EGF receptor tyrosine kinase inhibitors and ALK inhibitors. The treatment of patients with resistance to these agents is currently a field of intensive research. Numerous other oncogenic driver mutations have been discovered and corresponding agents are currently being tested in preclinical and clinical studies. Genomics in lung cancer and the field of miRNA in particular hold great promise.